Iron Deficiency Anemia Management

Introduction

• Iron deficiency anemia is a common condition that requires prompt evaluation and management, as recommended by the American Gastroenterological Association 1

Immediate Management

• Patients with iron deficiency anemia should receive oral iron supplementation immediately with ferrous sulfate 200mg three times daily, as recommended by the American Gastroenterological Association and the European Society of Gastroenterology 1, 2
• Iron replacement therapy should not be deferred while awaiting investigations unless colonoscopy is imminent, as recommended by the American Gastroenterological Association and the European Society of Gastroenterology 1, 2

Required Investigations

• Upper GI endoscopy with small bowel biopsies should be performed to rule out celiac disease and other upper GI causes of iron deficiency anemia, as recommended by the European Society for Gastrointestinal Endoscopy 2
• Colonoscopy or barium enema should be considered unless a firm cause is found with upper GI endoscopy, to investigate lower gastrointestinal causes of iron deficiency anemia, as recommended by the American Gastroenterological Association 1
• Screening for H. pylori and eradication if present should be performed, as recommended by the American College of Gastroenterology 2
• Urinalysis should be performed to exclude hematuria, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 1
• A comprehensive laboratory workup for anemia should include complete blood count with indices, reticulocyte count, serum ferritin, transferrin saturation, and C-reactive protein as the minimum initial tests, according to the Journal of Crohn's and Colitis guidelines 3

Treatment and Monitoring

• First-line treatment for iron deficiency anemia is oral iron supplementation with ferrous sulfate 200mg three times daily, as recommended by the American Gastroenterological Association, with a duration of three months after correction of anemia to replenish iron stores 1
• Alternative preparations such as ferrous gluconate or ferrous fumarate are equally effective if ferrous sulfate is not tolerated, as recommended by the European Society for Gastrointestinal Endoscopy 1
• Parenteral iron should be reserved for cases with intolerance to at least two oral preparations or non-compliance, as recommended by the American College of Gastroenterology 1
• Hemoglobin should be monitored within 4 weeks of starting therapy and at 3-month intervals for one year, with additional follow-up at 2 years, as recommended by the American Gastroenterological Association 1
• The following monitoring schedule is recommended:

Diagnostic Considerations

• Faecal occult blood testing is not recommended as it is insensitive and non-specific, as stated by the American Gastroenterological Association and the European Society of Gastrointestinal Endoscopy 1, 2
• Upper GI endoscopy is mandatory as 30-50% of IDA causes are found in the upper GI tract, and dual pathology (lesions in both upper and lower GI tracts) occurs in 10-15% of patients, according to the European Society of Gastrointestinal Endoscopy 1
• Small bowel biopsies should be taken during endoscopy to rule out celiac disease (present in 2-3% of IDA cases), as recommended by the European Society of Gastrointestinal Endoscopy 1
• Urinalysis to exclude hematuria (urinary tract tumors can rarely present with IDA) is essential, as suggested by the American Gastroenterological Association 1
• Consider screening for medication-induced blood loss by documenting use of aspirin, NSAIDs, and anticoagulants, as advised by the American College of Gastroenterology 1

Special Considerations

• For premenopausal women, the American College of Obstetricians and Gynecologists recommends considering gynecological causes of iron deficiency anemia, such as menstrual blood loss or pregnancy, based on low-quality evidence 4
• The Infectious Diseases Society of America recommends eradicating H. pylori if present in patients with recurrent IDA, based on high-quality evidence 2
• First-line therapy for H. pylori eradication in areas with low clarithromycin resistance is standard triple therapy for 14 days, consisting of a proton pump inhibitor (PPI) standard dose twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1000 mg twice daily, as recommended by 5
• Alternative therapy for areas with high clarithromycin resistance is sequential therapy for 10 days, consisting of PPI + amoxicillin for the first 5 days, followed by PPI + clarithromycin + metronidazole for the next 5 days, as recommended by 5